[{"id":"d3399d53-3142-4fb8-8731-3da5f0cf0026","acronym":"TITAN-RCC","url":"https://clinicaltrials.gov/study/NCT02917772","created_at":"2021-08-04T19:53:08.805Z","updated_at":"2025-02-25T14:36:42.250Z","phase":"Phase 2","brief_title":"Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Renal Cell Carcinoma","source_id_and_acronym":"NCT02917772 - TITAN-RCC","lead_sponsor":"AIO-Studien-gGmbH","biomarkers":" CD8 • PD-1 • PD-L2 • IL2RA • CD69 • ICOS • IL10 • CD14 • CD27 • LAMP1 • ITGAM • FAS • FOXP3 • IL17A • IL3RA • ITGAX • B3GAT1 • CD1C • CLEC4C","pipe":" | ","alterations":" PD-L1 expression","tags":["CD8 • PD-1 • PD-L2 • IL2RA • CD69 • ICOS • IL10 • CD14 • CD27 • LAMP1 • ITGAM • FAS • FOXP3 • IL17A • IL3RA • ITGAX • B3GAT1 • CD1C • CLEC4C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab)"],"overall_status":"Completed","enrollment":" Enrollment 200","initiation":"Initiation: 10/01/2016","start_date":" 10/01/2016","primary_txt":" Primary completion: 10/01/2021","primary_completion_date":" 10/01/2021","study_txt":" Completion: 10/01/2022","study_completion_date":" 10/01/2022","last_update_posted":"2022-10-06"},{"id":"da30e10f-e520-4977-a09e-302d2f4b6b4d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04001101","created_at":"2021-01-18T19:39:57.498Z","updated_at":"2024-07-02T16:36:20.116Z","phase":"Phase 2","brief_title":"Anti-PD-1 +/- RT for MSI-H Solid Tumors","source_id_and_acronym":"NCT04001101","lead_sponsor":"University of Colorado, Denver","biomarkers":" MSI • CD8 • LAG3 • IL2RA • ICOS • CD1C • CD80","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MSI • CD8 • LAG3 • IL2RA • ICOS • CD1C • CD80"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 10/10/2019","start_date":" 10/10/2019","primary_txt":" Primary completion: 11/17/2021","primary_completion_date":" 11/17/2021","study_txt":" Completion: 11/17/2021","study_completion_date":" 11/17/2021","last_update_posted":"2021-11-30"},{"id":"9124ed9d-dc00-4a0c-8f8f-dc3fa8b0b658","acronym":"","url":"https://clinicaltrials.gov/study/NCT03707808","created_at":"2022-03-23T23:54:56.024Z","updated_at":"2024-07-02T16:36:36.778Z","phase":"Phase 1","brief_title":"Intratumoral Injection of Autologous CD1c (BDCA-1)+ myDC, Avelumab, and Ipilimumab Plus Systemic Nivolumab","source_id_and_acronym":"NCT03707808","lead_sponsor":"Universitair Ziekenhuis Brussel","biomarkers":" CD1C","pipe":"","alterations":" ","tags":["CD1C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • Bavencio (avelumab)"],"overall_status":"Completed","enrollment":" Enrollment 9","initiation":"Initiation: 01/29/2018","start_date":" 01/29/2018","primary_txt":" Primary completion: 12/24/2020","primary_completion_date":" 12/24/2020","study_txt":" Completion: 12/24/2020","study_completion_date":" 12/24/2020","last_update_posted":"2020-12-29"},{"id":"fc4905d7-3fcb-4ad3-a4cc-487be3ac09b7","acronym":"myDCTV","url":"https://clinicaltrials.gov/study/NCT03747744","created_at":"2021-01-18T18:22:47.034Z","updated_at":"2024-07-02T16:36:36.754Z","phase":"Phase 1","brief_title":"Intratumoral Injection of Autologous CD1c (BDCA-1)+ Myeloid Dendritic Cells Plus Talimogene Laherparepvec (T-VEC)","source_id_and_acronym":"NCT03747744 - myDCTV","lead_sponsor":"Universitair Ziekenhuis Brussel","biomarkers":" PD-L1 • CD1C","pipe":"","alterations":" ","tags":["PD-L1 • CD1C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imlygic (talimogene laherparepvec)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 09/28/2018","start_date":" 09/28/2018","primary_txt":" Primary completion: 10/01/2023","primary_completion_date":" 10/01/2023","study_txt":" Completion: 10/01/2023","study_completion_date":" 10/01/2023","last_update_posted":"2020-12-29"}]